What is histiocytic sarcoma?
Histiocytic sarcoma is a very rare and usually aggressive cancer of histiocytes. Histiocytes are immune cells, closely related to macrophages, that live in tissues and help clear infections and damaged cells.
In histiocytic sarcoma, these cells become cancerous and form tumours. It can start in lymph nodes, the skin, the bowel, soft tissues, the spleen or almost anywhere else in the body.
The World Health Organization (WHO) groups it with the histiocytic and dendritic cell neoplasms, alongside Langerhans cell histiocytosis and Erdheim-Chester disease (Khoury et al., 2022). Unlike those conditions, histiocytic sarcoma is a true malignant sarcoma, with cells that look clearly cancerous under the microscope.
It is extremely rare, with roughly 0.17 new cases per million people each year (Kommalapati et al., 2018). It can occur at any age but is most common in adults in their 50s to 70s.
Some cases develop in people who have, or have had, another blood cancer, such as follicular lymphoma or chronic lymphocytic leukaemia. The lymphoma cells appear to change into histiocytic cells, a process called transdifferentiation (Skala et al., 2018).
When the disease is limited to one place, surgery and radiotherapy can control it for a long time. When it is widespread, it is harder to treat, but newer targeted drugs offer hope for some patients.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Malignant tumour of tissue histiocytes (macrophage-type cells) |
| How common | Very rare; about 0.17 per million people per year |
| Typical age | Any age; median in the early 60s |
| Common sites | Lymph nodes, skin, gut, soft tissue, spleen, liver, lungs, brain |
| Key markers | CD163, CD68, lysozyme |
| Gene changes | Often in the MAPK pathway (KRAS, NRAS, BRAF, MAP2K1) |
| Main treatments | Surgery and radiotherapy for localised disease; chemotherapy and targeted drugs for widespread disease |
| Outlook | Better when localised; often serious when widespread |
2. Causes and risk factors
In most people, histiocytic sarcoma has no known cause. It is not infectious and is not usually inherited.
| Risk factor | Notes |
|---|---|
| Older age | Most people are over 50 |
| Previous or current lymphoma or leukaemia | Especially follicular lymphoma, chronic lymphocytic leukaemia and, in children, acute lymphoblastic leukaemia |
| Mediastinal germ cell tumour | Rarely, histiocytic sarcoma develops alongside these tumours in young men |
| Male sex | Slightly more common in men in population studies |
Gene changes
Studies of tumour tissue show that most histiocytic sarcomas carry changes that switch on the MAPK (RAS-RAF-MEK-ERK) signalling pathway (Shanmugam et al., 2019).
| Gene | Notes |
|---|---|
| KRAS and NRAS | Among the most common changes |
| BRAF, including BRAF V600E | Found in a minority; may respond to BRAF inhibitors |
| MAP2K1 | Encodes MEK1; may respond to MEK inhibitors |
| PTPN11, NF1 and others | Less common MAPK pathway changes |
| CDKN2A loss | Often found alongside MAPK changes |
These changes occur only in the tumour. Testing for them matters because some can be targeted with tablets.
Where it fits among histiocytic disorders
Histiocytic disorders range from harmless to aggressive. The Histiocyte Society classification places histiocytic sarcoma in the “M” group of malignant histiocytoses (Emile et al., 2016).
| Group | Examples | Behaviour |
|---|---|---|
| L group | Langerhans cell histiocytosis, Erdheim-Chester disease | Variable; often chronic |
| R group | Rosai-Dorfman disease | Often mild; may settle without treatment |
| C group | Skin histiocytoses such as juvenile xanthogranuloma | Usually benign |
| M group | Histiocytic sarcoma, Langerhans cell sarcoma, interdigitating dendritic cell sarcoma | Malignant |
| H group | Haemophagocytic lymphohistiocytosis | Severe immune overactivation |
3. How does it look
On the body
| Site | Typical appearance |
|---|---|
| Lymph nodes | Firm, swollen nodes in the neck, armpit or groin |
| Skin | Red, purple or skin-coloured lumps or plaques, sometimes ulcerated |
| Soft tissue | A deep lump that may grow quickly |
| Bowel | A mass or thickening of the bowel wall, sometimes causing a blockage |
| Spleen and liver | Enlargement, sometimes with nodules on scans |
| Brain | One or more masses on MRI |
Tumours outside the lymph nodes, such as in the gut or soft tissue, often form a single large mass and can be mistaken for carcinoma or melanoma until special stains are done (Hornick et al., 2004).
On scans
CT or PET-CT scans show masses or enlarged organs that usually take up a lot of glucose tracer on PET. These findings are not specific; they can look like lymphoma or other cancers, so a biopsy is always needed.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Large, round to oval cells with plenty of pink cytoplasm |
| Nuclei | Large, irregular nuclei, often with prominent nucleoli |
| Pattern | Sheets of cells that wipe out the normal tissue |
| Background | Often mixed with inflammatory cells |
| Mitoses | Usually frequent, reflecting fast growth |
| Phagocytosis | Occasional tumour cells engulf other cells |
Special stains
The diagnosis depends on showing that the cancer cells are histiocytes and not lymphoma, carcinoma, melanoma or another sarcoma (Hung and Qian, 2020).
| Marker | Result in histiocytic sarcoma |
|---|---|
| CD163, CD68, lysozyme | Positive (histiocyte markers) |
| CD4, CD11c, CD14 | Often positive |
| S100 | Negative or only weak and patchy |
| CD1a and langerin (CD207) | Negative (positive in Langerhans cell tumours) |
| CD21, CD23, CD35 | Negative (positive in follicular dendritic cell sarcoma) |
| MPO, CD34 | Negative (helps exclude myeloid sarcoma) |
| B-cell, T-cell and keratin markers | Negative |
4. Symptoms
Symptoms depend on where the tumour grows and how widespread it is.
Common symptoms
- A lump or swelling, often in the neck, armpit or groin
- Skin lumps or patches that grow
- Fever without an infection
- Night sweats
- Weight loss without trying
- Tiredness and weakness
- Loss of appetite
Symptoms by site
| Site | Possible symptoms |
|---|---|
| Bowel | Tummy pain, vomiting, blood in stool, signs of bowel blockage |
| Spleen and liver | Fullness or pain under the ribs, feeling full quickly |
| Bone marrow | Anaemia (tiredness, breathlessness), infections, easy bruising |
| Lungs | Cough, breathlessness, chest pain |
| Brain | Headache, seizures, weakness, confusion, changes in vision |
| Bone | Bone pain or a fracture after minor injury |
When to seek medical advice
See a doctor if you have:
- A lump that persists for more than 2-3 weeks or keeps growing
- Fevers, drenching night sweats or weight loss without an obvious cause
- New neurological symptoms, such as a seizure or weakness
These symptoms are much more often caused by common conditions, but they need to be checked.
5. Diagnosis
| Test | Purpose |
|---|---|
| Biopsy | Essential; a surgical or core biopsy gives enough tissue for stains |
| Immunohistochemistry | Confirms histiocytic origin and excludes other cancers |
| Molecular testing | Looks for MAPK pathway changes that can be targeted |
| Blood tests | Blood count, liver and kidney function, LDH |
| PET-CT | Shows where the disease is in the body (staging) |
| MRI of the brain | If there are neurological symptoms |
| Bone marrow biopsy | If blood counts are abnormal or the disease is widespread |
| Review for previous lymphoma | Comparing samples can show if the sarcoma grew from an earlier lymphoma |
Because it is so rare, the biopsy should be reviewed by a specialist haematopathologist experienced in histiocytic disorders. International consensus recommendations for the diagnosis and treatment of malignant histiocytic neoplasms were published in 2026 (Goyal et al., 2026).
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Diffuse large B-cell lymphoma | B-cell markers positive |
| Anaplastic large cell lymphoma | CD30 and T-cell markers positive |
| Langerhans cell sarcoma | CD1a and langerin positive |
| Follicular dendritic cell sarcoma | CD21, CD23 and CD35 positive |
| Myeloid sarcoma | Myeloid markers such as MPO or CD34 positive |
| Melanoma | S100, SOX10 and melanoma markers positive |
| Carcinoma | Keratin positive |
6. Treatment
There is no single standard treatment, because the disease is so rare. Treatment is guided by how widespread it is, the person’s general health and the tumour’s gene changes. Care is best given at a centre with experience in histiocytic disorders.
Localised disease
| Treatment | Notes |
|---|---|
| Surgery | Complete removal of a single tumour where possible |
| Radiotherapy | After surgery, or instead of surgery when the tumour cannot be removed |
| Chemotherapy | Sometimes added for higher-risk localised disease |
People with a single, small tumour removed completely have the best outlook (Kommalapati et al., 2019).
Widespread disease
| Treatment | Notes |
|---|---|
| Combination chemotherapy | Lymphoma-type regimens such as CHOP or ICE are often used; responses vary |
| MEK inhibitors | Cobimetinib or trametinib for tumours with MAPK pathway changes; cobimetinib produced responses in histiocytic neoplasms in a phase 2 trial (Diamond et al., 2019) |
| BRAF inhibitors | For tumours with the BRAF V600E mutation, often combined with a MEK inhibitor |
| Stem cell transplant | Autologous or allogeneic transplant may be considered after a good response in fit patients |
| Radiotherapy | To control individual tumours or relieve pain |
| Clinical trials | Strongly encouraged |
In the United States, cobimetinib was approved in 2022 for adults with histiocytic neoplasms, which can include histiocytic sarcoma.
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, wound problems, effects depending on the organ involved |
| Radiotherapy | Skin soreness, tiredness, local effects depending on the area |
| Chemotherapy | Low blood counts, infections, nausea, hair loss, tiredness, nerve damage |
| MEK and BRAF inhibitors | Rash, diarrhoea, swelling, fever, eye problems, heart and muscle effects |
| Stem cell transplant | Infections, graft-versus-host disease (allogeneic), long recovery |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Chemotherapy | Given through a drip in cycles every 2-3 weeks, usually as a day patient |
| Targeted tablets | Taken at home with regular check-ups, blood tests and eye checks |
| Radiotherapy | Short daily sessions on weekdays over 2-5 weeks |
| Scans | PET-CT every few months to check the response |
7. Outlook (prognosis)
| Situation | Approximate outlook |
|---|---|
| Single tumour, completely removed | Long-term survival is possible; some people are cured |
| Widespread disease | Often serious; median survival measured in months in older series |
| All cases together | Median survival about 6 months in a population-based study (Kommalapati et al., 2018) |
These figures come from older data, collected before targeted drugs were widely used. Responses to MEK and BRAF inhibitors have been deep and long-lasting in some patients, so outcomes may now be better for people whose tumours carry targetable changes.
Factors linked with a better outlook
- Localised disease (one site only)
- Small tumour that can be completely removed
- Good general health
- Response to first treatment
- A targetable gene change
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic visits | Every 2-3 months at first, to check symptoms and examine for lumps |
| Blood tests | Blood count, liver function, LDH |
| PET-CT or CT scans | Regularly in the first years to detect recurrence |
| Monitoring on targeted drugs | Eye checks, heart scans and skin checks as needed |
9. Living with histiocytic sarcoma
- Ask for a specialist centre; experience with histiocytic disorders matters
- Ask about molecular testing, as it can open up targeted treatment options
- Report fevers promptly during chemotherapy
- Keep active as much as possible to maintain strength
- Eat well and ask for a dietitian if you are losing weight
- Seek emotional support from counsellors and histiocytosis patient groups
- Ask about palliative care early; it helps control symptoms at any stage
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is histiocytic sarcoma a lymphoma? | No, but it is a blood-related cancer and is often treated by lymphoma specialists; some cases develop from a lymphoma |
| Is it the same as Langerhans cell histiocytosis? | No. Both involve histiocytic-type cells, but histiocytic sarcoma is a more aggressive cancer with different markers |
| Is it inherited? | No |
| Can it be cured? | Sometimes, especially when it is found in one place and completely removed |
| Why is gene testing important? | Some gene changes can be treated with targeted tablets |
| Can children get it? | Rarely; some cases in children follow acute lymphoblastic leukaemia |
11. Questions to ask your care team
- Has the diagnosis been confirmed by an expert pathologist?
- Is the disease localised or widespread?
- Has the tumour been tested for MAPK pathway changes such as BRAF or KRAS?
- Am I a candidate for targeted therapy or a clinical trial?
- Would a stem cell transplant be an option for me?
- What side effects should I report straight away?
Resources
- Diamond, E.L. et al. (2019) ‘Efficacy of MEK inhibition in patients with histiocytic neoplasms’, Nature, 567(7749), pp. 521-524.
- Emile, J.F. et al. (2016) ‘Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages’, Blood, 127(22), pp. 2672-2681.
- Goyal, G. et al. (2026) ‘Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas)’, Blood, 148(3), pp. 275-288.
- Hornick, J.L., Jaffe, E.S. and Fletcher, C.D. (2004) ‘Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy’, American Journal of Surgical Pathology, 28(9), pp. 1133-1144.
- Hung, Y.P. and Qian, X. (2020) ‘Histiocytic sarcoma’, Archives of Pathology and Laboratory Medicine, 144(5), pp. 650-654.
- Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms’, Leukemia, 36(7), pp. 1703-1719.
- Kommalapati, A. et al. (2018) ‘Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes’, Blood, 131(2), pp. 265-268.
- Kommalapati, A. et al. (2019) ‘Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma’, Leukemia and Lymphoma, 60(2), pp. 553-555.
- Shanmugam, V. et al. (2019) ‘Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma’, Modern Pathology, 32(6), pp. 830-843.
- Skala, S.L., Lucas, D.R. and Dewar, R. (2018) ‘Histiocytic sarcoma: review, discussion of transformation from B-cell lymphoma, and differential diagnosis’, Archives of Pathology and Laboratory Medicine, 142(11), pp. 1322-1329.
Prepared by the editorial team, October 2026.